Form 4: Acrivon Therapeutics Director Acquires Stock Options Under RA Capital Arrangement

Director Derek DiRocco acquired stock options in Acrivon Therapeutics, but disclaims beneficial ownership due to an arrangement with RA Capital Management.

Summary

• Derek DiRocco, a director of Acrivon Therapeutics, acquired 20,275 stock options on June 20, 2024, exercisable at $6.52.
• The options vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to continuous service.
• DiRocco disclaims beneficial ownership of these options and the underlying common stock because he holds them for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P.
• Any proceeds from exercising the options will offset advisory fees owed by these funds to RA Capital Management, L.P.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing, indicating standard insider activity. The arrangement with RA Capital is a neutral factor, suggesting a professional relationship. Overall, the sentiment is neutral to slightly positive due to the director's acquisition of stock options.

Future Outlook

The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through each applicable vesting date.

Industry Context

This filing reflects standard practice for reporting transactions by company insiders, particularly directors, and highlights arrangements where beneficial ownership is disclaimed due to external agreements, which is common with investment firms like RA Capital.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for corporate insiders in the US, ensuring transparency in their trading activities.
• Similar filings are common across publicly traded companies, such as those in the biotechnology sector like Amgen or Gilead, when directors or officers engage in stock transactions.
• The arrangement with RA Capital, where the director holds options for the benefit of the fund, is not uncommon in the investment management industry, and similar arrangements can be seen with other funds like OrbiMed or Flagship Pioneering.

Related Party Transactions

• The arrangement between Derek DiRocco and RA Capital Management, L.P., where DiRocco holds the stock options for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P., constitutes a related party transaction.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions.
• The arrangement with RA Capital may indirectly benefit the funds and their investors.

Key Dates